Replies to post #233575 on Biotech Values

[DewDiligence]

CYAD—(-38%)—axes allogeneic CAR-T for MM, which was the company's only clinical program:

https://finance.yahoo.com/news/celyad-oncology-provides-strategic-business-060000281.html